Cycling vs continuous use of strength peptides

Cycling — running a peptide for a defined period and then taking time off — is the default approach for most strength peptides. The reasons range from "well-supported" to "precautionary," and they vary by peptide class. Continuous indefinite use isn't always wrong, but the threshold for it should be high.

Why cycle at all

Three reasons, in order of how well-supported each is:

Receptor desensitization is the strongest mechanistic reason. If your goal is achieved (the tendon healed, the gut is calmer), cycling is just common sense. The long-term safety unknown is the precautionary case — pre-clinical safety data is short-duration, and continuous human use over years isn't well-characterized for any of these compounds.

By peptide class — recommended cycling pattern

BPC-157 / TB-500 (recovery peptides)

Reasoning: recovery peptides are tools for specific repair goals. Once the goal is met, the rationale for continuing is thin. The pre-clinical record is on healing models, not chronic preventive use. Continuous angiogenic signaling has theoretical (not demonstrated) cancer concerns.

GH secretagogues — short-acting (Ipamorelin, CJC-1295 no DAC, Sermorelin)

Reasoning: short-acting secretagogues preserve the natural pulsatile pattern, which limits receptor desensitization concerns. The pituitary still controls release. Cycling is more about rotating the stimulus and giving the GH axis a normal-physiology window than about avoiding tachyphylaxis.

GH secretagogues — long-acting (CJC-1295 DAC, MK-677)

Reasoning: sustained-elevation formulations produce more receptor downregulation over time. Side-effect drift (insulin sensitivity, water retention, carpal tunnel symptoms) is more pronounced with continuous use. MK-677 specifically has documented insulin-sensitivity issues on multi-month continuous runs.

Tesamorelin

Tesamorelin is the one secretagogue with FDA-approval for chronic use, and the trial data supports continuous administration in the approved indication. For off-label use, cycling makes more sense.

What "off" actually means

A few practical clarifications:

• "Off" means zero dose — not "lower dose"
• The off period should be at least one full half-life × 5 for the peptide
• Stacking peptides with different schedules complicates this — if you're running BPC-157 daily and TB-500 weekly, the cycle "end" is when both have been zero for the off-period
• For long-acting peptides (CJC with DAC, Tesamorelin), the off period needs to account for their long half-lives

What cycling does not solve

A few common misconceptions:

• Cycling doesn't reset accumulated side effects. If you ran MK-677 for 6 months and your fasting glucose drifted, a 4-week off period doesn't necessarily restore baseline. Some metabolic shifts take longer to reverse — and some may not fully reverse.
• Cycling doesn't prevent long-term safety risks. If continuous indefinite use carries risk, intermittent indefinite use carries some fraction of that risk. Cycling reduces but doesn't eliminate.
• Cycling doesn't mean "back to identical baseline." Your hormonal milieu is shaped by what you've run before. The body remembers.

When continuous use makes sense

Despite the cycling defaults, continuous use is sometimes defensible:

• Sermorelin at low maintenance dose (200 mcg/night) for sleep quality — preserves natural pulse, low receptor-desensitization concern
• BPC-157 oral at low maintenance dose for chronic GI conditions — under medical supervision, with regular monitoring
• Tesamorelin for the FDA-approved indication
• Brief continuous bridges between cycles where cycling would interrupt a critical training block

The threshold should be: the goal genuinely requires continuous administration, the side-effect tracking is in place, and the user has informed-consent understanding of what's known and unknown about long-term use.

Cycle-end check-in

Whatever cycle length you run, the end-of-cycle reassessment is the most important part:

1. Did you meet the goal? Define this before starting. "Recovery from Achilles issue" is measurable; "feel better" is not.
2. Track objective markers — bloodwork at baseline and end-of-cycle, body-comp metrics if relevant, pain/mobility scales for recovery use
3. Track subjective markers — sleep, mood, energy, recovery
4. If the goal is met, stop. Don't drift into a new cycle without a goal.
5. If the goal isn't met, evaluate whether the protocol or the diagnosis is the problem. Sometimes the peptide isn't the right tool.
6. If side effects accumulated, pay attention. The next cycle won't be more tolerable.

A reasonable framework

For most strength-peptide users, the simple framework:

• Default to cycling. Don't run anything continuously by default.
• Cycle length matches the goal. Recovery peptides 4–6 weeks; secretagogues 12 weeks.
• Off period is at least 50% of cycle length. 6 weeks on → 3+ weeks off; 12 weeks on → 6+ weeks off.
• Plan cycles around training, not the other way around. If you have a heavy training block, plan a recovery-peptide cycle to support it. Don't disrupt training to fit an arbitrary cycle.
• Document. Every cycle. Subjective and objective.

Related reading

• When to stop a peptide cycle
• BPC-157 side effects
• GH secretagogue side effects
• Vendor quality checks